---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-053665"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2023-11-16T23:59:59+00:00"
generated_at: "2026-06-08T01:01:20.426209+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ADMA receives FDA approval for 10th plasma collection center; achieves plasma supply self-sufficiency

## Summary
- FDA approval for Laurel, MD facility (10th ADMA BioCenters center) to introduce source plasma into interstate commerce.
- Facility began operations and collection in H1 2023; now licensed for further manufacturing in the U.S.
- Management says approval accomplishes goal of plasma self-sufficiency, supporting revenue growth and profitability outlook.
- Center uses Haemonetics NexSys Persona® collection system; expects ~50 staff at full capacity.

## SEC filing metadata
- accession: 0001140361-23-053665
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2023-11-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036123053665/0001140361-23-053665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036123053665/ef20014835_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-053665
- JSON: https://secwatch.observer/filing/0001140361-23-053665.json
- Plain text: https://secwatch.observer/filing/0001140361-23-053665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.